Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study. Issue 6 (June 2021)

• Record Type: Journal Article
• Authors: Culié, Dorian; Schiappa, Renaud; Modesto, Anouchka; Viotti, Julien; Chamorey, Emmanuel; Dassonville, Olivier; Poissonnet, Gilles; Bizeau, Alain; Vergez, Sebastien; Dupret-Bories, Agnes; Fakhry, Nicolas; Santini, Laure; Lallemant, Benjamin; Chambon, Guillaume; Sudaka, Anne; Peyrade, Frederic; Saada-Bouzid, Esma; Benezery, Karen; Jourdan-Soulier, Florence; Chapel, Françoise; Ramay, Anne Sophie; Roger, Pascal; Galissier, Thibault; Coste, Valérie; Ben Lakdar, Aicha; Guerlain, Joanne; Mirghani, Haitham; Gorphe, Phillipe; Guelfucci, Bruno; Garrel, Renaud; Temam, Stephane; Bozec, Alexandre;
• Is Part Of: European journal of surgical oncology. Volume 47:Issue 6(2021)
• Page Start: 1389
• Page End: 1397
• Publication Date: 2021-06
• Subjects: Oropharynx -- Cancer -- Human papilloma virus -- Surgery -- Radiotherapy -- Survival; S surgery -- RT radiotherapy -- CT chemotherapy -- OS overall survival -- DSS disease-specific-survival -- RFS recurrence-free survival -- MTB multidisciplinary tumor board; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2020.12.011
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.